Phase 2 trials used once-weekly subcutaneous injections ranging from 1 mg to 12 mg, with higher doses associated with greater weight reduction but more gastrointestinal side effects
Expert Tips For the best experience: Maintain a healthy skincare routine
The injection technique is identical to what you would use for semaglutide injections or tirzepatide stomach injections
Oltre alla risalita di rigurgito acido, i pazienti possono manifestare: nausea e vomito, con irritazione faringea e laringea, tosse secca o cronica, correlata al reflusso laringo-faringeo (extra-esofageo), laringospasmo e disfonia, da irritazione laringea, in rari casi, possono comparire faringiti e infezioni delle alte vie respiratorie, gi comunque segnalate nei trial clinici
Clin Diabetes (2014) 32:3243
Because obesity significantly increases the risk for cardiovascular diseases such as heart failure, it could be an indirect cardioprotective action